CFDE Data Portal | Search CLCA4-AS1

	Label	Description
	CLCA4-AS1 Gene (Entity type)	ENSG00000236915 - CLCA4 antisense RNA 1
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE143782 calcitriol 7 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434,GSE202438 6 V 11 TALAZOPARIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 15 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE213650 3 V 2 EVEROLIMUS HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE143782 calcitriol 6 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE101754 FXR1 knockdown NCI-H358 5 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 12 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS

CLCA4-AS1

ENSG00000236915 - CLCA4 antisense RNA 1

GSE202434 GSE202438 talazoparib 6 v 11 human up

A Gene Set from LINCS

GSE143782 calcitriol 7 v 11 human dn

A Gene Set from LINCS

GSE162892 ISOX 3 v 2 human dn

A Gene Set from LINCS

GSE202434,GSE202438 6 V 11 TALAZOPARIB HUMAN UP

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 15 v 11 human up

A Gene Set from LINCS

GSE213650 3 V 2 EVEROLIMUS HUMAN UP

A Gene Set from LINCS

GSE143782 calcitriol 6 v 5 human up

A Gene Set from LINCS

GSE101754 FXR1 knockdown NCI-H358 5 v 2 human dn

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 12 v 11 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.